Pharmacologic C5-complement suppression reduces blood loss during on-pump cardiac surgery

Area of Science:

• Cardiovascular Surgery
• Immunology
• Pharmacology

Background:

• Inflammation and complement activation are linked to morbidity, bleeding, and tissue injury after on-pump cardiac surgery.
• Cardiopulmonary bypass can trigger complement system activation, exacerbating adverse outcomes.
• This study investigated the role of complement C5 suppression using pexelizumab in mitigating these effects.

Purpose of the Study:

• To evaluate the pharmacology of pexelizumab, a C5 complement inhibitor.
• To assess the impact of pexelizumab on postoperative blood loss in cardiac surgery patients.
• To determine the efficacy of pexelizumab in suppressing complement activation during cardiopulmonary bypass.

Main Methods:

• A Phase II multicentered clinical trial involving 914 patients undergoing cardiac surgery (CABG or CABG with valve surgery).
• Patients were randomized to receive pexelizumab as a bolus, a continuous infusion, or placebo.
• Assessed pexelizumab pharmacokinetics, chest tube drainage, and blood product transfusion requirements.

Main Results:

• Pexelizumab completely suppressed complement-dependent hemolytic activity within 1 hour.
• Continuous infusion of pexelizumab prolonged the duration of complement suppression compared to bolus administration alone.
• A reduction in chest tube drainage was observed in all pexelizumab-treated groups, with similar transfusion requirements across all groups.

Conclusions:

• Pexelizumab effectively inhibits complement-dependent hemolytic activity in patients undergoing cardiac surgery with cardiopulmonary bypass.
• Pexelizumab administration is associated with reduced postoperative chest tube drainage.
• Further clinical investigation is warranted to establish the therapeutic value of complement attenuation in this patient population.